These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 16167050)

  • 1. Targeting Bcl-2 protein expression in solid tumors and hematologic malignancies with antisense oligonucleotides.
    Tolcher AW
    Clin Adv Hematol Oncol; 2005 Aug; 3(8):635-42, 662. PubMed ID: 16167050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis.
    Frankel SR
    Semin Oncol; 2003 Apr; 30(2):300-4. PubMed ID: 12720157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apoptosis, Bcl-2 antisense, and cancer therapy.
    Piro LD
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 10):5-10. PubMed ID: 15651171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oligonucleotide therapeutics: clothing the emperor.
    Gewirtz AM
    Curr Opin Mol Ther; 1999 Jun; 1(3):297-306. PubMed ID: 11713794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy.
    Kim R; Emi M; Tanabe K; Toge T
    Cancer; 2004 Dec; 101(11):2491-502. PubMed ID: 15503311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential therapeutic applications of oblimersen in CLL.
    Koziner B
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 10):32-8. PubMed ID: 15651175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bcl-2 antisense therapy in B-cell malignancies.
    Chanan-Khan A
    Blood Rev; 2005 Jul; 19(4):213-21. PubMed ID: 15784299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor regression by combination antisense therapy against Plk1 and Bcl-2.
    Elez R; Piiper A; Kronenberger B; Kock M; Brendel M; Hermann E; Pliquett U; Neumann E; Zeuzem S
    Oncogene; 2003 Jan; 22(1):69-80. PubMed ID: 12527909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oblimersen in the treatment of metastatic melanoma.
    Tarhini AA; Kirkwood JM
    Future Oncol; 2007 Jun; 3(3):263-71. PubMed ID: 17547520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bcl-2 antisense therapy in hematologic malignancies.
    Chanan-Khan A
    Curr Opin Oncol; 2004 Nov; 16(6):581-5. PubMed ID: 15627020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy.
    Kim R; Emi M; Matsuura K; Tanabe K
    Cancer Gene Ther; 2007 Jan; 14(1):1-11. PubMed ID: 17041564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. G3139 induces cell death by caspase-dependent and -independent apoptosis on human melanoma cell lines.
    Nakamura S; Inui M; Kamei T; Nakase M; Okumura K; Tagawa T
    Oncol Rep; 2006 Jun; 15(6):1563-8. PubMed ID: 16685396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.
    Zhang C; Pei J; Kumar D; Sakabe I; Boudreau HE; Gokhale PC; Kasid UN
    Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Proapoptotic therapy with oblimersen (bcl-2 antisense oligonucleotide)--review of preclinical and clinical results].
    Büchele T
    Onkologie; 2003 Dec; 26 Suppl 7():60-9. PubMed ID: 14716145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential roles of antisense therapy in the molecular targeting of genes involved in cancer (review).
    Kim R; Tanabe K; Emi M; Uchida Y; Toge T
    Int J Oncol; 2004 Jan; 24(1):5-17. PubMed ID: 14654935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.
    Bedikian AY; Millward M; Pehamberger H; Conry R; Gore M; Trefzer U; Pavlick AC; DeConti R; Hersh EM; Hersey P; Kirkwood JM; Haluska FG;
    J Clin Oncol; 2006 Oct; 24(29):4738-45. PubMed ID: 16966688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antisense therapy of hematologic malignancies.
    Cotter FE
    Semin Hematol; 1999 Oct; 36(4 Suppl 6):9-14. PubMed ID: 10530711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reprogramming cell death: BCL2 family inhibition in hematological malignancies.
    Scarfò L; Ghia P
    Immunol Lett; 2013; 155(1-2):36-9. PubMed ID: 24095849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bcl-2-targeted antisense therapy (Oblimersen sodium): towards clinical reality.
    Moreira JN; Santos A; Simões S
    Rev Recent Clin Trials; 2006 Sep; 1(3):217-35. PubMed ID: 18473975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia.
    Yu B; Mao Y; Bai LY; Herman SE; Wang X; Ramanunni A; Jin Y; Mo X; Cheney C; Chan KK; Jarjoura D; Marcucci G; Lee RJ; Byrd JC; Lee LJ; Muthusamy N
    Blood; 2013 Jan; 121(1):136-47. PubMed ID: 23165478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.